Mostrando 4 resultados de: 4
Filtros aplicados
Subtipo de publicación
Article(4)
Área temáticas
Enfermedades(4)
Farmacología y terapéutica(2)
Mammalia(1)
Medicina y salud(1)
Microorganismos, hongos y algas(1)
Origen
scopus(4)
A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer
ArticleAbstract: Nimotuzumab is a humanized IgG1 monoclonal antibody against the EGFR extracellular domain that has bPalabras claves:Advanced cervical cancer, eGFR, Monoclonal antibody, nimotuzumab, Pilot studyAutores:Astudillo H., Avila S., Bazán B., Bojalil R., Cetina L., Charco E., Coronel J., Dueñas-Gonzãlez A., Jiménez-Lima R., Ramos M., Tania Crombet, Zapata S.Fuentes:scopusEvaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials
ArticleAbstract: Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: hPalabras claves:Epidermal growth factor receptor, Head and neck tumors, Humanized monoclonal antibody, nimotuzumabAutores:Aliuska Frías, Carmen Elena Viada, García L., Mabel Álvarez, Macías A.E., Mestre B.F., Osorio M., Pérez Ruiz L., Ramos M., Robaina M., Santiesteban Y., Tania Crombet, Vega A.M.Fuentes:scopusImmune, inflammatory and prothrombotic parameters in COVID-19 patients treated with an anti EGFR antibody
ArticleAbstract: SARS-CoV-2 infection causes a range of clinical presentations and induces changes in both innate andPalabras claves:covid-19, eGFR, inflammation, nimotuzumab, SARS-COV-2, T cellsAutores:Añe-Kouri A.L., Armada J.J., González Y.Z., Gregorich E.M.L., Londres H.D., Luaces P.L.o., Martínez A.H., Medel L., Mena J., Ramos M., Saavedra Hernández D., Sánchez Y.H., Tania Crombet, Troche M.Fuentes:scopusSystemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab
ArticleAbstract: Nimotuzumab (h-R3) is a humanized anti-epidermal growth factor receptor monoclonal antibody (mAb) rePalabras claves:animal model, CETUXIMAB, Epidermal growth factor receptor, General toxicity, H-R3, Monkeys, nimotuzumab, Skin toxicityAutores:Arteaga M.E., Ballester-Labrada A., Baro F., Boleda M., Casacó Parada A.R., Charro L., Fuentes D., García M., González B., González C., Hernández O., Ledón N., Macías A.E., Morales Y., Orphee R., Pardo B., Pérez A., Ramos M., Rodríguez V., Rodriquez L., Subirós N., Tania Crombet, Viña L.Fuentes:scopus